Workflow
Benzinga
icon
搜索文档
Ross Stores Stock Rises 5.5% After Key Trading Signal
Benzinga· 2025-05-27 20:35
公司动态 - Ross Stores Inc (ROST) 在5月23日上午10:09出现Power Inflow信号 交易价格为13050美元 该信号被活跃交易者视为看涨指标 可能预示股价上行趋势 [3][4] - Power Inflow信号通常出现在市场开盘后两小时内 反映机构资金动向 对当日剩余交易时段的股价方向有指引作用 [6] - 信号触发后 ROST股价最高达13777美元 收盘报13746美元 较信号触发价分别上涨56%和53% [8] 交易信号分析 - Power Inflow属于订单流分析范畴 通过分解零售与机构订单流量 分析买卖订单规模 时间等特征 辅助交易决策 [5] - 该信号表明机构资金("聪明钱")正在流入 交易者可将其作为潜在入场点 捕捉预期上涨行情 [4] - 订单流分析能帮助市场参与者更准确解读市场状况 识别交易机会 但需结合风险管理策略 [7] 数据服务 - Benzinga Pro提供ROST期权交易的实时警报服务 数据来源包括TradePulse等合作机构 [8]
Why Is Prothena Stock Trading Lower On Tuesday?
Benzinga· 2025-05-27 19:43
Prothena Corporation plc PRTA released data from the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL amyloidosis on Friday.AL (amyloid light-chain) amyloidosis is a systemic disease where abnormal proteins, called amyloid fibrils, accumulate in various organs. It’s the most common type of systemic amyloidosis.The Phase 3 AFFIRM-AL trial enrolled 207 newly diagnosed patients. Birtamimab was given to the active arm every 28 days at a dose level of 24 mg/kg (maximum dose not to excee ...
Top Wall Street Forecasters Revamp Okta Expectations Ahead Of Q1 Earnings
Benzinga· 2025-05-27 17:17
Okta shares fell 0.2% to close at $123.72 on Friday. Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables. Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period. Okta, Inc. OKTA will release its first-quarter earnings results after the closing bell on Tuesday, May 27. Analysts expect the San Francisco, California-based company to ...
PDD Holdings Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Benzinga· 2025-05-27 10:27
PDD Holdings Inc. PDD will release its first-quarter earnings results before the opening bell on Tuesday, May 27. Analysts expect the Dublin, Ireland-based company to report quarterly earnings at $2.49 per share. According to data from Benzinga Pro, PDD Holdings projects to report quarterly revenue at $14.17 billion. On March 21, PDD Holdings reported fourth-quarter earnings that missed revenue expectations. PDD Holdings shares fell 0.5% to close at $119.24 on Friday. Benzinga readers can access the latest ...
Apple May Hike iPhone Price, But 'Well Positioned' To Eat Tariff Bite, Says Analyst
Benzinga· 2025-05-27 01:46
A fresh wave of tariff threats is hanging over Apple Inc AAPL, but JPMorgan's Samik Chatterjee isn't downgrading Apple stock. In fact, he's sticking to an Overweight rating, calling the company "well positioned" to weather the cost shock.With the Donald Trump administration reportedly mulling a 25% tariff on iPhones made abroad, Chatterjee admits that "tariffs would increase likelihood of iPhone price increase." But he doesn't see this as a major threat to Apple's fundamentals.Read Also: iTariff Threat: Tru ...
Palantir: The Only Cathie Wood Pick Among S&P 500's Top Performers
Benzinga· 2025-05-27 00:46
The S&P 500's leaderboard for 2024 features some surprising names and familiar heavyweights. At the top sits NRG Energy Inc NRG, scorching ahead with over 70% gain year-to-date, fueled by a rally in power demand and clean energy transitions. Hot on its heels is heavyweight Palantir Technologies Inc PLTR, posting a strong 64% YTD surge, making it the only stock from Cathie Wood's ARK Invest universe to crack the S&P 500's top-performing list.Other solid performers include Howmet Aerospace Inc HWM (+49% YTD), ...
UroGen Pharma Stock Receives Downgrade As Analyst Cites FDA Panel Setback For Key Bladder Cancer Drug
Benzinga· 2025-05-26 02:16
评级调整 - HC Wainwright & Co分析师Raghuram Selvaraju将UroGen Pharma Ltd(URGN)评级从买入下调至中性 因FDA肿瘤药物咨询委员会以5-4投票结果反对其候选疗法UGN-102的收益风险比 [1] - 该疗法(丝裂霉素膀胱灌注溶液)针对复发性低级别中危非肌层浸润性膀胱癌患者 [1] 审批前景 - 微弱劣势的投票结果大幅降低了UGN-102及时获批的可能性 [2] - 若下月获批 唯一条件将是要求开展上市后随机对照试验 此情形将促使重新评估当前评级 [3] 财务状况 - 公司2025年第一季度末持有约2亿美元现金及等价物 预计可维持运营至2026年底 [4] - 分析师将2026年每股净亏损预测从盈利0.27美元调整为亏损2.14美元 [4] 研发管线进展 - 正在开发下一代丝裂霉素制剂UGN-103和UGN-104 分别作为UGN-102和JELMYTO的升级版 [5] - 采用RTGel递送平台与medac GmbH授权的新型丝裂霉素配方 [5] - UGN-103针对同类适应症的3期UTOPIA试验正在入组 预计2025年中完成 阳性结果可能推动2026年提交申请 2027年获批 [6] 股价表现 - 公司股票上周五收盘报4.19美元 [6]
Trump's Trade Spat With Europe And Apple Revives Tariff Risks For S&P 500
Benzinga· 2025-05-24 04:29
Just as Wall Street seemed as though a sense of stability was finally seeping into 2025, President Trump served a timely reminder that tariff uncertainty will continue to drive market volatility. The President announced that he would be "recommending" sweeping 50% tariffs on all European Union imports, due to start on June 1, as a result of a perceived lack of progress in trade negotiations with the bloc. Trump elaborated that factors like the EU's trade barriers, VAT taxes, corporate penalties, non-monetar ...
Intuit's AI Strategy, Upmarket Gains Fuel Analyst Optimism Following Strong Earnings
Benzinga· 2025-05-24 04:05
Wall Street analysts rerated Intuit Inc INTU after the company reported its third-quarter results on Thursday.Intuit reported third-quarter revenue of $7.75 billion, up 15%, beating analyst estimates of $7.56 billion. The QuickBooks and TurboTax parent company reported third-quarter adjusted earnings of $11.65 per share, beating analyst estimates of $10.91 per share.Also Read: Intuit Under-performance Has Stemmed From Valuation Reset, Analyst Upgrades StockIntuit expects fourth-quarter revenue of $3.72 bill ...
Hewlett Packard, NetApp Better Positioned To Sidestep Tariff Headwinds Ahead of Earnings: Analyst
Benzinga· 2025-05-24 03:26
JP Morgan analyst Samik Chatterjee shared earnings previews for several prominent hardware companies, cautioning that these firms may contend with ongoing demand uncertainty and renewed tariff risks in their upcoming earnings reports.Chatterjee sees another round of conservative results in the coming week, with stock movements more likely to reflect how investors interpret management’s efforts to either de-risk the second half of the year or contain expectations for potential full-year downside, especially ...